A prescription, a consent form, and Australia's first confirmed peptide death

On Wednesday, October 28, 2026, the Coroners Court of Victoria published its findings on the death of Richard Norton: Australian martial artist, actor and stunt coordinator, the man who staged the fights in Mad Max: Fury Road and Furiosa, dead at 75 on March 30, 2025, at The Alfred hospital in Melbourne. Coroner David Ryan found that he died of complications that arose from his use of unapproved peptide products CJC1295 and Ipamorelin. The products had been prescribed by a doctor and made by a licensed compounding pharmacy in Queensland. It is, in the words reported by the ABC, believed to be the first confirmed fatality in Australia from unapproved peptide use.

This piece sets out what the coroner found, what the same two molecules looked like to the United States Food and Drug Administration three years earlier, why a prescription and a consent form changed nothing about them, and why the country that could learn most from Victoria is at this moment building the same pipeline at scale. Those are facts with sources; the conclusions are ours.

What the coroner found

The sequence in the findings, as reported, is short. In March 2025 Norton went to a doctor about fatigue, reduced physical recovery, shoulder pain and the loss of lean muscle mass. He was 75, with asthma, osteoarthritis and two reconstructed shoulders behind him. The doctor and he discussed what the findings call the experimental nature of the treatment and the potential risks and the lack of other alternative treatment options currently approved by the TGA. Blood tests and imaging were arranged. He signed an Informed Consent Form for Peptide Therapy that listed anaphylaxis among the risks. The doctor prescribed CJC-1295 and ipamorelin, off-label, and a compounding pharmacy supplied them.

Days later he told the doctor he was feeling good. On March 28 he told a clinic nurse that he had been administering double the prescribed dose. The nurse advised him to use only the prescribed amount from the following week. Hours after that conversation, after using the two products, he felt hot and flushed and became unresponsive. He suffered a cardiac arrest and died two days later. The coroner found he had been taking amounts of the medication in excess of the dose prescribed by his medical practitioner.

The recommendation is the part that matters beyond one family. Mr Ryan asked the Therapeutic Goods Administration, Australia's medicines regulator, to review the therapeutic benefits and safety risks of peptides such as CJC1295 and Ipamorelin and to consider whether further restrictions ought to be imposed on their use. He went further than a request for a review: I am not satisfied that it is appropriate for them to be available to be prescribed by medical practitioners.

The Medical Board had already looked at the doctor. Its expert, Professor Alistair Vickery, reported that There is insufficient evidence that CJC1295/Ipamorelin is safe, effective or beneficial for human use, found the clinical care was at a standard reasonably expected, and called the documentation sparse, inadequate and perfunctory. The Board found the practice is or may be unsatisfactory and issued a caution with conditions in July 2026. Read those two sentences together. The expert says the evidence that these molecules are safe for a person does not exist; the Board says prescribing them anyway was within the standard expected. That is not a contradiction in the Board's reasoning. It is a description of the system.

What FDA said about the same two molecules in 2023

None of this was news to a regulator. On September 29, 2023, the FDA placed CJC-1295 and ipamorelin acetate, with BPC-157, AOD-9604 and LL-37, in Category 2 of its interim policy on bulk substances for section 503A compounding, the category for substances with significant safety risks. The stated basis was risk for immunogenicity, peptide-related impurities, and limited safety-related information. Immunogenicity is the regulator's word for the immune system taking a foreign peptide for an invader; anaphylaxis is its most violent form. The impurities point is the one this library spends most of its pages on: a synthetic peptide is never the single molecule on its label, and the related substances that come with it are exactly the things an immune system notices. Where the two molecules sit on FDA's lists today has shifted with the politics; what FDA found about them in 2023 has not been answered by any new data we can find.

Both molecules have reference entries in this library, built from their structures: CJC-1295 without DAC, a 29-residue amide with four substitutions in the growth hormone–releasing hormone sequence, and ipamorelin, a pentapeptide amide with two D-amino acids and an unnatural residue. Those entries say what the molecules are and what a spectrum of them should show. They say nothing about what the molecules do in a person, because nothing in the record does, and the Medical Board's own expert said so.

A prescription changed nothing about the molecule

The instinct, reading this story, is to file it under the wrong heading: a man bought something online and used too much of it. He did not. He went to a doctor. He had blood tests and imaging first. He signed a form that named the risk that killed him. The product was made by a licensed pharmacy under a prescription. Every box the respectable version of this market asks to be ticked was ticked, and the outcome was the one the 2023 FDA memo described. The form said experimental, and a consent form that has to say that is a confession: the data that would let anyone call the product safe was not there to consent to.

That is the point we keep making about the research-use line, and this is the week to make it plainly. A research-use-only product is sold with an analytical record: identity by mass spectrometry, purity by HPLC, net content, a certificate matched to a lot. That record is complete for what it covers and silent on everything else, and the silence is honest. It says: this is what the molecule is; what it does in a body is unknown. A product page that dresses that silence in wellness language is lying by omission. A prescription that dresses it in a consent form is doing the same thing with better paperwork. The molecule does not know which paperwork it came with.

Victoria has a number nobody in the United States collects. Its chief health officer has reported 13 cases of anaphylaxis associated with unapproved peptide use since July 2025, five of them in September alone. Thirteen is a small number against the scale of the market and a large one against zero, which is what the public record said a year ago. It is also what a surveillance system looks like when it is switched on. The lesson of the Norton findings is not that one man miscounted. It is that a market was running on a safety record that did not exist, and the first time anyone looked properly, this is what they found.

The United States is building the pipeline anyway

Last week this library covered the HHS enforcement-discretion notice: on October 28, over the objections of most of FDA's scientific reviewers, the department said it would not enforce against pharmacies compounding six other peptides under section 503A. The reviewers' briefing documents had found the substances not well characterized for identity, purity and quality, the same three words the Australian coroner's file turns on. CJC-1295 and ipamorelin are not on that list of six. They do not need to be. They are already the staple pairing of the American telehealth peptide clinic, prescribed by video, compounded by a pharmacy in another state, shipped with a consent form. Victoria's doctor, nurse, blood tests and consent form were, by that standard, the careful version.

The Australian response, within a day, was to ask for the pipeline to be examined. Dr Monique Ryan, the independent federal member for Kooyong, called for a parliamentary inquiry into online-only clinics, their vertically integrated pharmacy and retail models, and gaps in the regulation and oversight of prescribing for medicines with high potential for misuse. Her words: His death should be a turning point, and The system allowed it. That's the problem. The TGA said it continues to warn consumers about the risks of unapproved peptides which have not been assessed by the TGA for safety, quality or effectiveness and is considering whether further regulatory or other measures may be appropriate. The American response the same week was to widen the gate. A regulator that pushes molecules with this record toward pharmacies, over its own reviewers, is choosing to find out the way Victoria found out.

What this means for a research supplier

It means the line is where the evidence is, and this library will keep it there. The pages here describe molecules: structure, mass, purity, how to read the certificate that comes with them, what a spectrum should show and what it cannot. They do not describe what a molecule does in a person, and questions about that get no answer from us, because the honest answer is the one the Medical Board's expert gave. It also means we will not pretend the research-use label is a technicality. It is the only accurate label these molecules have. The alternative labels on offer this year, experimental on a consent form in Melbourne and enforcement discretion in a Federal Register notice in Washington, are not more accurate. They are permission slips for the same unknown.

Richard Norton spent fifty years making violence look survivable on screen and teaching actors to do the same. He did the responsible thing with a product nobody had characterized for the use he put it to, and it killed him. The coroner's recommendation is modest: review the evidence, consider restrictions. We would put it less politely. Until someone produces the data the 2023 memo asked for, there is no responsible version of this, with or without a prescription.

What to watch

• The TGA review. The coroner's recommendation goes to the regulator, which has said it is assessing further measures. Any scheduling change or compounding restriction for CJC-1295 and ipamorelin will be the first direct regulatory consequence of a peptide death anywhere.
• The parliamentary inquiry. Whether the House Health Committee takes up the online-clinic reference, and whether the vertically integrated clinic-pharmacy model is examined as a model rather than as individual practitioners.
• Victoria's anaphylaxis count. Thirteen since July 2025 is the first such series published by any jurisdiction. If the chief health officer keeps publishing it, it becomes the safety record that the 2023 FDA memo said was missing.
• The HHS docket. Comments on the enforcement-discretion policy for six other peptides close two weeks after October 30. The Norton findings arrived in time to be cited in them.

Frequently asked questions

Were the products research chemicals bought online?

No. They were prescribed by a doctor after blood tests and imaging, made by a licensed compounding pharmacy in Queensland, and supplied with a signed consent form. The coroner's recommendation concerns whether they should be available on prescription at all.

Did the coroner find that the peptides caused the death?

The finding is that he died of complications arising from his use of the two unapproved products, that he collapsed and suffered a cardiac arrest after using them, and that he had been using more than the amount prescribed. The consent form had listed anaphylaxis as a risk.

What had FDA said about CJC-1295 and ipamorelin?

On September 29, 2023, FDA placed both in Category 2 of its interim 503A compounding policy, citing risk for immunogenicity, peptide-related impurities, and limited safety-related information. Their position on FDA's lists has moved since; the underlying record has not.

Does this change anything for research-use-only materials?

Not in law. It confirms what the label already says: the analytical record is all that exists for these molecules, and it describes what they are, not what they do in a person. Anyone who asks the second question of a research supplier should expect no answer.

Is this piece neutral?

The facts are cited. The conclusions, including the view that there is no responsible version of this use until the missing data exists, are ours and are labeled as opinion.

Sources & Further Reading

1. Coroners Court of Victoria, Coroner David Ryan. Findings into the death of Richard Norton, handed down October 28, 2026, as reported by the Australian Broadcasting Corporation: Coroner recommends TGA review peptide restrictions after Australian actor's death, ABC News, October 29, 2026.
2. The New Daily and Australian Associated Press. Aussie actor's death linked to unapproved peptides, October 29, 2026.
3. The Medical Republic. Peptide-related death spurs call for telehealth inquiry, October 29, 2026, including the Victorian chief health officer's count of anaphylaxis cases associated with unapproved peptide use since July 2025.
4. Office of Dr Monique Ryan MP, Member for Kooyong. Coroner's findings on peptide death show urgent need for telehealth inquiry, media release, October 29, 2026.
5. Food and Drug Administration. Interim policy on bulk drug substances under section 503A: categories update of September 29, 2023, placing AOD-9604, BPC-157, LL-37, CJC-1295 and ipamorelin acetate in Category 2. Copy hosted by the Alliance for Pharmacy Compounding.
6. Variety. Richard Norton, 'Mad Max' Series Actor and Hollywood Stunt Coordinator, Dies at 75, April 2025.
7. This library: Six peptides, two legal lives: the HHS enforcement-discretion notice; What "research use only" means in law; Questions we don't answer, and why.

Cosmic Peptides. (2026, October 29). A prescription, a consent form, and Australia's first confirmed peptide death. Cosmic Peptides Research Library. Retrieved October 30, 2026, from https://cosmicpeptides.com/research/perspectives/the-first-confirmed-death

@misc{cosmicpeptides_research_perspectives_the_first_confirmed_death,
  author       = {{Cosmic Peptides}},
  title        = {A prescription, a consent form, and Australia's first confirmed peptide death},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = oct,
  url          = {https://cosmicpeptides.com/research/perspectives/the-first-confirmed-death},
  urldate      = {2026-10-30},
  note         = {Last reviewed 2026-10-29}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - A prescription, a consent form, and Australia's first confirmed peptide death
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/10/29
UR  - https://cosmicpeptides.com/research/perspectives/the-first-confirmed-death
Y2  - 2026/10/30
LA  - en
ER  -